Compare LAW & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | WHWK |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.0M | 187.4M |
| IPO Year | 2021 | N/A |
| Metric | LAW | WHWK |
|---|---|---|
| Price | $4.12 | $3.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $8.00 | $7.50 |
| AVG Volume (30 Days) | 210.2K | ★ 485.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,849,000.00 | N/A |
| Revenue This Year | $11.23 | N/A |
| Revenue Next Year | $10.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $2.45 | $1.57 |
| 52 Week High | $9.11 | $5.50 |
| Indicator | LAW | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 57.62 | 35.56 |
| Support Level | $3.77 | $3.24 |
| Resistance Level | $4.52 | $3.79 |
| Average True Range (ATR) | 0.24 | 0.21 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 74.42 | 21.21 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.